Clinical Trials Logo

Metastatic Nasopharyngeal Cancer clinical trials

View clinical trials related to Metastatic Nasopharyngeal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05385926 Recruiting - Clinical trials for Metastatic Nasopharyngeal Cancer

Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

Start date: May 5, 2022
Phase: Phase 2
Study type: Interventional

Incidences of de novo metastatic nasopharyngeal carcinoma range from 6% to 8% at the time of presentation. For the initial diagnosis of metastatic NPC, PD-1 plus chemotherapy yields a satisfactory outcome with1year PFS of 40%. Previous study demonstrated the benefit of adding radiotherapy to chemotherapy in metastatic NPC, however there is no evidence whether radiotherapy can further improve PFS based on chemotherapy plus PD-1 . The purpose of this study is to evaluate the safety and effectiveness of first-line immunochemotherapy combined with radiotherapy for initial diagnosed metastatic NPC.

NCT ID: NCT05198479 Recruiting - Clinical trials for Metastatic Nasopharyngeal Cancer

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

SG-AAA-II-01
Start date: May 5, 2023
Phase: Phase 2
Study type: Interventional

This study is the first phase II study of 177Lu-DOTA0-Tyr3-Octreotate in metastatic NPC. Patients whom have failed 2 or more lines of therapy or exhausted standard therapy and are avid on 68Ga-DOTATATE imaging will be eligible to receive up to 4 cycles of 177Lu-DOTA0-Tyr3-Octreotate. The primary outcome will be progression free survival at 6 months.

NCT ID: NCT03813394 Not yet recruiting - Clinical trials for Metastatic Nasopharyngeal Cancer

Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC

2018/00947
Start date: May 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).

NCT ID: NCT03007836 Completed - Clinical trials for Metastatic Nasopharyngeal Cancer

High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer

Start date: December 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of nasopharyngeal cancer.